Compounds > naamidine a
Page last updated: 2024-10-15

naamidine a

Description

naamidine A: isolated from the sponge Leucetta; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135455949
CHEMBL ID339727
MeSH IDM0295926

Synonyms (10)

Synonym
110189-06-5
naamidine a
CHEMBL339727 ,
bdbm50066984
4-(5-(4-hydroxybenzyl)-4-(4-methoxybenzyl)-1-methyl-1h-imidazol-2-ylamino)-1-methyl-1h-imidazole-2,5-dione
5-[5-(4-hydroxy-benzyl)-4-(4-methoxy-benzyl)-1-methyl-1h-imidazol-2-ylamino]-3-methyl-imidazole-2,4-dione
5-[[5-[(4-hydroxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]-1-methylimidazol-2-yl]amino]-3-methylimidazole-2,4-dione
4-((5-(4-hydroxybenzyl)-4-(4-methoxybenzyl)-1-methyl-1h-imidazol-2-yl)amino)-1-methyl-1h-imidazole-2,5-dione
DTXSID40149164
(5z)-5-[5-[(4-hydroxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]-1-methylimidazol-2-yl]imino-3-methylimidazolidine-2,4-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Insulin receptorMus musculus (house mouse)IC50 (µMol)242.00000.20000.20000.2000AID93075
Epidermal growth factor receptorMus musculus (house mouse)IC50 (µMol)11.30000.08100.09050.1000AID69721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID138452In vivo inhibitory activity against A431 tumor implanted in athymic mice at 25 mg/kg (number of deaths)1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID307589Inhibition EGF-dependent mitogenesis of mouse BaF/ERX cells by [3H]thymidine incorporation assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and biological evaluation of analogues of the anti-tumor alkaloid naamidine A.
AID69721Inhibition of Epidermal growth factor receptor mediated mitogenesis of NIH3T3 cells1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID138453In vivo inhibitory activity against A431 tumor implanted in athymic mice at 3.13 mg/kg (number of deaths)1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID134879In vivo inhibitory activity against A431 tumor implanted in athymic mice at 50 mg/kg (number of deaths)1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID93075Inhibition of insulin receptor mediated mitogenesis of NIH3T3 cells1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID138451In vivo inhibitory activity against A431 tumor implanted in athymic mice at 12.5 mg/kg (number of deaths)1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
AID233386Selectivity for EGF over insulin receptors1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		2.03101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
bax 439
Bax 439: decreases concentrating ability of kidney; RN given refers to parent cpd		2.0310
2-aminoimidazole
2-aminoimidazole: from catabolism of arginine		7.1110
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		6.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Epidermoid
[description not available]		01.9910
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9910
Experimental Neoplasms
[description not available]		02.0510